利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.054 秒)

    YKL-40 monoclonal authority
    14.
    发明授权
    YKL-40 monoclonal authority 有权
    YKL-40单克隆抗体

    公开(公告)号：US08053563B2

    公开(公告)日：2011-11-08

    申请号：US11817244

    申请日：2006-02-16

    申请人： Richard Bonnichsen ,  Paul Price

    发明人： Richard Bonnichsen ,  Paul Price

    IPC分类号： C07K16/00

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/73

    摘要： The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.

    摘要翻译： 本发明涉及能够调节其中YKL-40起突出作用的生物学过程的单克隆抗人YKL-抗体。 抑制细胞，特别是癌细胞的生长和/或诱导细胞凋亡。 本发明还涉及包含所述抗体的药物组合物，并且使用所述抗体和/或药物组合物来治疗疾病，其中抑制细胞生长，细胞分裂，细胞外基质的重塑，转移和/或由细胞凋亡引起的细胞死亡的诱导是 成功治愈的先决条件。 本发明的抗体能够通过与YKL-40上的特异性表位结合而在上述方法中抑制YKL-40的生物学功能。

    YKL-40 MONOCLONAL AUTHORITY
    15.
    发明申请
    YKL-40 MONOCLONAL AUTHORITY 有权
    YKL-40单克隆抗体

    公开(公告)号：US20090175870A1

    公开(公告)日：2009-07-09

    申请号：US11817244

    申请日：2006-02-16

    申请人： Richard Bonnichsen ,  Paul Price

    发明人： Richard Bonnichsen ,  Paul Price

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K5/00 ,  C07K7/00 ,  C12N5/06 ,  A61K38/08

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/73

    摘要： The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.

    摘要翻译： 本发明涉及能够调节其中YKL-40起突出作用的生物学过程的单克隆抗人YKL-抗体。 抑制细胞，特别是癌细胞的生长和/或诱导细胞凋亡。 本发明还涉及包含所述抗体的药物组合物，并且使用所述抗体和/或药物组合物来治疗疾病，其中抑制细胞生长，细胞分裂，细胞外基质的重塑，转移和/或由细胞凋亡引起的细胞死亡的诱导是 成功治愈的先决条件。 本发明的抗体能够通过与YKL-40上的特异性表位结合而在上述方法中抑制YKL-40的生物学功能。

    Investment analysis and reporting system and method
    16.
    发明申请
    Investment analysis and reporting system and method 审中-公开
    投资分析报告制度与方法

    公开(公告)号：US20060106700A1

    公开(公告)日：2006-05-18

    申请号：US11076310

    申请日：2005-03-08

    申请人： Michael Boren ,  David Boren ,  Douglas Bates ,  Christopher Growney ,  Charles Dunn ,  James Dunn ,  Jerek Anderson ,  Paul Price ,  Brian Hill ,  Justin Reed ,  James Price

    发明人： Michael Boren ,  David Boren ,  Douglas Bates ,  Christopher Growney ,  Charles Dunn ,  James Dunn ,  Jerek Anderson ,  Paul Price ,  Brian Hill ,  Justin Reed ,  James Price

    IPC分类号： G07F19/00 ,  G06Q40/00 ,  G07B17/00

    CPC分类号： G06Q20/4016 ,  G06Q40/00 ,  G06Q40/06 ,  G06Q40/12

    摘要： A method and system for analyzing and reporting institutional investments provides a single platform for daily investment accounting, compliance, performance, and risk reports for investment portfolios held at single or multiple custody/safekeeping locations. The method involves retrieving transaction data from multiple independent financial institutions and storing it in a database in a standardized format and retrieving security data from one or more security information service providers and storing it in the database. The method further involves applying a uniform set of customized accounting, compliance, risk and performance parameters to the transaction data and security data stored in the database and, in response to a user request, calculating and reporting selected data to the user in accordance with the uniform accounting, compliance, risk and performance parameters.

    摘要翻译： 分析和报告机构投资的方法和系统为单一或多个保管/保管地点的投资组合的日常投资会计，合规性，绩效和风险报告提供了单一平台。 该方法包括从多个独立的金融机构检索交易数据，并将其以标准格式存储在数据库中，并从一个或多个安全信息服务提供商检索安全数据并将其存储在数据库中。 该方法还包括将统一的定制会计，合规性，风险和性能参数集合应用于存储在数据库中的交易数据和安全数据，并且响应于用户请求，根据用户请求计算和报告所选择的数据给用户 统一的会计，合规性，风险和绩效参数。